Teleflex Incorporated (TFX)
$
120.78
-0.16 (-0.13%)
Key metrics
Financial statements
Free cash flow per share
10.4810
Market cap
5.5 Billion
Price to sales ratio
1.8366
Debt to equity
0.4896
Current ratio
2.2768
Income quality
3.9986
Average inventory
622.1 Million
ROE
0.0343
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for various diagnostic and therapeutic procedures in critical care and surgical settings globally. The company recorded an operating income of $151,013,000.00 reflecting its earnings from core operations. It provides vascular access products that include Arrow branded catheters, catheter navigation and tip positioning systems, as well as intraosseous access systems for intravenous therapies, blood pressure measurement, and blood sample withdrawal through a single puncture site. The cost of revenue for the company is $1,344,645,000.00 showcasing its production and operational expenses. Additionally, the company earned an interest income of $8,009,000.00 showcasing its financial investments, while the net total of other income and expenses is -$75,535,000.00 reflecting non-core financial activities. Among its offerings are interventional products, which feature various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products utilized by interventional cardiologists, radiologists, and vascular surgeons, including Arrow branded catheters and the Manta Vascular Closure. The diluted EPS is $1.48 accounting for potential share dilution. Teleflex also supplies anesthesia products, surgical tools, interventional urology solutions, and respiratory care devices, catering to a diverse range of healthcare needs. The stock is reasonably priced at $120.78 appealing to a broad range of investors. With a mid-range market capitalization of $5,337,147,420.00 the company is a steady performer and belongs to the Healthcare sector, driving innovation and growth. Additionally, the stock has a low average trading volume of 1,158,235.00 indicating lower market activity, making it an intriguing option for investors. It is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape while providing essential products and services to hospitals, healthcare providers, medical device manufacturers, and the home care market. As Teleflex continues to evolve, its strategic offerings are likely to maintain its presence within the healthcare sector, enhancing patient care and outcomes.
Is Teleflex Incorporated (TFX) a good investment?
Investing in Teleflex Incorporated (TFX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Teleflex Incorporated (TFX)'s stock forecast?
Analysts predict Teleflex Incorporated stock to fluctuate between $119.08 (low) and $249.91 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Teleflex Incorporated's market capitalization?
As of 2025-05-23, Teleflex Incorporated's market cap is $5,337,147,420, based on 44,189,000 outstanding shares.
How does Teleflex Incorporated compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Teleflex Incorporated has a Lower Market-Cap, indicating a difference in performance.
Does Teleflex Incorporated pay dividends?
Teleflex Incorporated pays dividends. The current dividend yield is 1.07%, with a payout of $0.34 per share.
How can I buy Teleflex Incorporated (TFX) stock?
To buy Teleflex Incorporated (TFX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TFX. Place an order (Market, Limit, etc.).
What is the best time to invest in Teleflex Incorporated?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Teleflex Incorporated stock ever split?
Teleflex Incorporated's last stock split was 2:1 on 1997-06-17.
How did Teleflex Incorporated perform in the last earnings report?
Revenue: $3,047,324,000 | EPS: $1.49 | Growth: -80.34%.
Where can I find Teleflex Incorporated's investor relations reports?
Visit https://www.teleflex.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Teleflex Incorporated?
You can explore historical data from here
What is the all-time high and low for Teleflex Incorporated stock?
All-time high: $449.38 (2021-04-28) | All-time low: $119.08 (2025-05-23).
What are the key trends affecting Teleflex Incorporated stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.
prnewswire.com
NEW YORK , May 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.
globenewswire.com
Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / WHY: New York, N.Y., May 15, 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / WHY: New York, N.Y., May 13, 2025.
See all news
